Pereira Renan A, Oliveira de Almeida Versiéri, Zambrano Mariana, Zhang Linjie, Amantéa Sérgio L
Department of Pediatrics Federal University of Health Sciences of Porto Alegre Porto Alegre Brazil.
Maternal-Infant Department, Faculty of Medicine Federal University of Rio Grande Rio Grande Brazil.
Health Sci Rep. 2022 Apr 18;5(3):e598. doi: 10.1002/hsr2.598. eCollection 2022 May.
Nebulized epinephrine and hypertonic saline have been extensively studied in infants with acute bronchiolitis, with conflicting results.
To evaluate the efficacy on length of stay (LOS), clinical severity scores (CSS), oxygen saturation (SaO), and safety profile of nebulized epinephrine plus hypertonic saline (HS) in infants with acute bronchiolitis.
MATERIALS & METHODS: This is a systematic review and meta-analysis. Outcomes were represented by mean differences (MD) or standard mean differences (SMD) and 95% confidence intervals (CIs) were utilized.
Eighteen trials were systematically selected and 16 of them contributed to the meta-analysis (1756 patients). Overall, a modest but significant positive impact was observed of the combination therapy on LOS (MD of -0.35 days, 95% CI -0.62 to -0.08, = 0.01, = 91%). Stratification by time of CSS assessment unveiled positive results in favor of the combination therapy in CSS assessed 48 and 72 h after the admission (SMD of -0.35, 95% CI -0.62 to -0.09, = 0.008, = 41% and SMD of -0.27, 95% CI -0.50 to -0.04, = 0.02, = 0%, respectively). No difference in SaO was observed. Additional data showed a consistent safety profile, with a low rate of adverse events (1%), most of them mild and transient.
Low-quality evidence from this systematic review suggests that nebulized epinephrine plus HS may be considered as a safe and efficient therapy for decreasing LOS and CSS in infants with acute bronchiolitis, especially in those who require hospitalization for more than 48 h.
雾化吸入肾上腺素和高渗盐水已在急性细支气管炎婴儿中得到广泛研究,但结果相互矛盾。
评估雾化吸入肾上腺素加用高渗盐水(HS)对急性细支气管炎婴儿住院时间(LOS)、临床严重程度评分(CSS)、血氧饱和度(SaO)的疗效及安全性。
这是一项系统评价和荟萃分析。结果以平均差(MD)或标准化平均差(SMD)表示,并采用95%置信区间(CI)。
系统筛选出18项试验,其中16项纳入荟萃分析(1756例患者)。总体而言,联合治疗对住院时间有适度但显著的积极影响(MD为-0.35天,95%CI为-0.62至-0.08,P = 0.01,I² = 91%)。按CSS评估时间分层显示,入院后48小时和72小时评估的CSS中,联合治疗有积极结果(SMD分别为-0.35,95%CI为-0.62至-0.09,P = 0.008,I² = 41%;SMD为-0.27,95%CI为-0.50至-0.04,P = 0.02,I² = 0%)。未观察到SaO有差异。其他数据显示安全性一致,不良事件发生率低(1%),大多数为轻度且短暂。
该系统评价的低质量证据表明,雾化吸入肾上腺素加用HS可被视为一种安全有效的治疗方法,用于缩短急性细支气管炎婴儿的住院时间和降低CSS,尤其是那些需要住院超过48小时的婴儿。